These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 29064441)

  • 1. Pattern Recognition of the Multiple Sclerosis Syndrome.
    Zabad RK; Stewart R; Healey KM
    Brain Sci; 2017 Oct; 7(10):. PubMed ID: 29064441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes.
    Lana-Peixoto MA; Talim N
    Biomedicines; 2019 Jun; 7(2):. PubMed ID: 31212763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide.
    Hor JY; Asgari N; Nakashima I; Broadley SA; Leite MI; Kissani N; Jacob A; Marignier R; Weinshenker BG; Paul F; Pittock SJ; Palace J; Wingerchuk DM; Behne JM; Yeaman MR; Fujihara K
    Front Neurol; 2020; 11():501. PubMed ID: 32670177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.
    Dos Passos GR; Oliveira LM; da Costa BK; Apostolos-Pereira SL; Callegaro D; Fujihara K; Sato DK
    Front Neurol; 2018; 9():217. PubMed ID: 29670575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports.
    Bellinvia A; Pastò L; Razzolini L; Fratangelo R; Prestipino E; Fonderico M; Tudisco L; Amato MP
    Mult Scler Relat Disord; 2019 Aug; 33():51-54. PubMed ID: 31152967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
    Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.
    Juryńczyk M; Jacob A; Fujihara K; Palace J
    Pract Neurol; 2019 Jun; 19(3):187-195. PubMed ID: 30530724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis.
    Caron-Cantin M; Cestari DM; Fortin E
    Curr Opin Ophthalmol; 2019 Nov; 30(6):412-417. PubMed ID: 31503075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
    Mariotto S; Ferrari S; Monaco S; Benedetti MD; Schanda K; Alberti D; Farinazzo A; Capra R; Mancinelli C; De Rossi N; Bombardi R; Zuliani L; Zoccarato M; Tanel R; Bonora A; Turatti M; Calabrese M; Polo A; Pavone A; Grazian L; Sechi G; Sechi E; Urso D; Delogu R; Janes F; Deotto L; Cadaldini M; Bianchi MR; Cantalupo G; Reindl M; Gajofatto A
    J Neurol; 2017 Dec; 264(12):2420-2430. PubMed ID: 29063242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease.
    Lotan I; Hellmann MA; Benninger F; Stiebel-Kalish H; Steiner I
    J Neuroimmunol; 2018 Nov; 324():115-118. PubMed ID: 30267996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.
    Salama S; Khan M; Levy M; Izbudak I
    Mult Scler Relat Disord; 2019 Apr; 29():15-22. PubMed ID: 30658259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential diagnosis of neuromyelitis optica spectrum disorders.
    Kim SM; Kim SJ; Lee HJ; Kuroda H; Palace J; Fujihara K
    Ther Adv Neurol Disord; 2017 Jul; 10(7):265-289. PubMed ID: 28670343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.